(Q47805811)

5 February 2018

title

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. (English)

1 reference

5 February 2018

author

Daniela Pietra

6

1 reference

5 February 2018

Francesco Passamonti

7

1 reference

5 February 2018

N Scott Reading

12

1 reference

5 February 2018

Robert Kralovics

17

1 reference

5 February 2018

author name string

D Olcaydu

1

1 reference

5 February 2018

R C Skoda

2

1 reference

5 February 2018

R Looser

3

1 reference

5 February 2018

S Li

4

1 reference

5 February 2018

M Cazzola

5

1 reference

5 February 2018

E Lippert

8

1 reference

5 February 2018

S Carillo

9

1 reference

5 February 2018

F Girodon

10

1 reference

5 February 2018

A Vannucchi

11

1 reference

5 February 2018

J T Prchal

13

1 reference

5 February 2018

C Ay

14

1 reference

5 February 2018

I Pabinger

15

1 reference

5 February 2018

H Gisslinger

16

1 reference

5 February 2018

publication date

14 May 2009

1 reference

5 February 2018

published in

Leukemia

1 reference

5 February 2018

volume

23

1 reference

5 February 2018

page(s)

1924-1926

1 reference

5 February 2018

issue

10

1 reference

5 February 2018

https://scigraph.springernature.com/pub.10.1038/leu.2009.110

exact match

0 references

cites work

The myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.110

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2009.110

1 reference

5 February 2018

PubMed ID

19440215

1 reference

5 February 2018